Akwasi Sarpong

Array ( [id] => 15270183 [patent_doc_number] => 20190383826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/459056 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16459056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15270181 [patent_doc_number] => 20190383825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/457331 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16457331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16306591 [patent_doc_number] => 10775375 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Methods for identifying modulators of calcium-sensing receptors [patent_app_type] => utility [patent_app_number] => 16/450462 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 36 [patent_no_of_words] => 12771 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898481 [patent_doc_number] => 20200148759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE [patent_app_type] => utility [patent_app_number] => 16/448341 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8451 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067284 [patent_doc_number] => 20210269499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => HEPATITIS B AND/OR HEPATITIS D-PERMISSIVE CELLS AND ANIMALS [patent_app_type] => utility [patent_app_number] => 17/254762 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675117 [patent_doc_number] => 20230312700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/253811 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 297222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336549 [patent_doc_number] => 10787493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Targeted modified TNF family members [patent_app_type] => utility [patent_app_number] => 16/441324 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 8327 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16441324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254203 [patent_doc_number] => 20190375835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/436537 [patent_app_country] => US [patent_app_date] => 2019-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17307368 [patent_doc_number] => 11208460 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Single-arm type I and type II receptor fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/423593 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 64617 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16423593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282510 [patent_doc_number] => 20200276112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => ADMINISTRATION REGIMEN OF COMPOSITIONS OF T4 THYROID HORMONE WITH HIGH ORAL ABSORPTION [patent_app_type] => utility [patent_app_number] => 16/421373 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19955331 [patent_doc_number] => 12325738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-10 [patent_title] => Treatment of CIDP [patent_app_type] => utility [patent_app_number] => 17/056632 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 5672 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17056632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956045 [patent_doc_number] => 11059887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Anti-claudin 18.2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/962817 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 24108 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932463 [patent_doc_number] => 20210198352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => Endogenous Labelling of Extracellular Vesicles [patent_app_type] => utility [patent_app_number] => 17/058130 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931731 [patent_doc_number] => 12304928 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Epitope restriction for antibody selection [patent_app_type] => utility [patent_app_number] => 17/053230 [patent_app_country] => US [patent_app_date] => 2019-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 81 [patent_no_of_words] => 50389 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976100 [patent_doc_number] => 20210220337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => METHODS OF MODULATING ANTIGENICITY TO ENHANCE RECOGNITION BY T-CELLS [patent_app_type] => utility [patent_app_number] => 17/055227 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19335 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -64 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209889 [patent_doc_number] => 20190367631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/407099 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638082 [patent_doc_number] => 12168683 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Binders of TGFb-superfamily ligands and uses thereof [patent_app_type] => utility [patent_app_number] => 17/052783 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 40 [patent_no_of_words] => 78966 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 336 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020608 [patent_doc_number] => 20220372107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/052785 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -174 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563421 [patent_doc_number] => 20220127570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => IMMUNE EFFECTOR CELL AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/052425 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060127 [patent_doc_number] => 11104714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Compositions comprising a P75 tumor necrosis factor receptor/Ig fusion protein [patent_app_type] => utility [patent_app_number] => 16/396352 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 7517 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16396352 [rel_patent_id] =>[rel_patent_doc_number] =>)